Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X7WK
|
||||
| Former ID |
DIB008721
|
||||
| Drug Name |
AZD-6553
|
||||
| Synonyms |
Neutrophil elastase inhibitor (oral, COPD), AstraZeneca/Quintiles
|
||||
| Indication | Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] | Discontinued in Phase 1 | [1] | ||
| Company |
AstraZeneca plc
|
||||
| Target and Pathway | |||||
| Target(s) | Leukocyte elastase | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Transcriptional misregulation in cancer | ||||
| Systemic lupus erythematosus | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| C-MYB transcription factor network | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | ||||
| Human Complement System | |||||
| Degradation of collagen | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703) | ||||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.